TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór piersi, który nie można operować, rozprzestrzeniony lokalnie lub na inne organy
- •Wyniki badań patologicznych lub laboratoryjnych wykonane w laboratorium certyfikowanym, znane przed rejestracją do badania
- •Historia raka piersi typu HER2-niska lub HER2-zero, nigdy wcześniej nie diagnozowana jako HER2-dodatnia
- •Posiada mierzalne zmiany nowotworu widoczne w badaniach obrazowych
- •Gotów do pobrania próbek guza do badań (przed leczeniem, po 3 tygodniach i podczas progresji choroby)
- •Jeśli nowotwór jest wrażliwy na hormony: wcześniej stosował leki hormonalne lub inhibitory CDK4/6
- •Nowotwór jest dostępny do bezpiecznego pobrania próbek biopsyjnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 24, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (11)
University of Alabama
Birmingham, United States
University of San Francisco
San Francisco, United States
Yale University Cancer Center
New Haven, United States
Georgetown University Medical Center
Washington D.C., United States
University of Chicago Medical Center
Chicago, United States
Beth Israel Deaconess Medical Center
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Montefiore Einstein Comprehensive Cancer Center
The Bronx, United States
University of North Carolina
Chapel Hill, United States
Vanderbilt Cancer Center
Nashville, United States
Baylor College of Medicine
Houston, United States
Trial contact
Ana Garrido-Castro, MD
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.